why choose us

300×250 Ad Slot

Research Article: Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review: PRELUDE1 prospective cohort study protocol

Date Published: 2023-05-19

Abstract:
Introduction Non-alcoholic fatty liver disease is the most common chronic liver disease worldwide affecting 20%–25% in the USA and Europe with a 60%–80%?lifetime prevalence for people with type 2 diabetes (T2D). Fibrosis has repeatedly been demonstrated to be the major determinant of liver disease morbidity and mortality and there is currently no routine screening for liver fibrosis in at-risk T2D population. Methods and analysis This 12-month prospective cohort study of automated fibrosis testing uses the fibrosis-4 score (FIB-4) in patients with T2D linked to the investigation of hospital-based versus community-based second-tier transient elastography (TE) testing. We plan to include >5000 participants across 10 General Practitioner (GP) practices in East London and Bristol. This will determine the rate of undiagnosed significant liver fibrosis in a T2D population, the feasibility of two-tier liver fibrosis screening using FIB-4 at the diabetes annual review and subsequent TE delivered either in the community or secondary care settings. This will include an intention-to-treat analysis for all those invited to attend for diabetes annual review. A qualitative substudy regarding the acceptability of the fibrosis screening pathway will comprise semistructured interviews/focus groups with primary care staff (GPs and practice nurses), and patients taking part in the wider study. Ethics and dissemination This study received a favourable opinion from the Cambridge East research ethics committee. The results of this study will be disseminated in peer-reviewed scientific journals, conference presentations and local diabetes lay panel meetings. Trial registration number ISRCTN14585543 .

Introduction:
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide affecting 20%–25% in the West 1 2 and 60%–80% of people with type 2 diabetes (T2D). 3 4 NAFLD is defined by excess liver fat and has a multidirectional relationship with the different elements of metabolic syndrome and comorbidities. Not all patients with NAFLD progress to advanced liver disease: approximately 1 in 6 people with NAFLD has the progressive form, non-alcoholic steatohepatitis (NASH). 5 NASH is characterised…

Read more

300×250 Ad Slot